These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 20362363)
21. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Yin T; Miyata T Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452 [TBL] [Abstract][Full Text] [Related]
22. Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort. Camilleri E; Ghobreyal M; Bos MHA; Reitsma PH; Van Der Meer FJM; Swen JJ; Cannegieter SC; van Rein N Pharmacotherapy; 2024 Jun; 44(6):416-424. PubMed ID: 38686648 [TBL] [Abstract][Full Text] [Related]
23. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342 [TBL] [Abstract][Full Text] [Related]
24. Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants. Mazur-Bialy AI; Zdebska K; Wypasek E; Undas A Thromb Res; 2013 Mar; 131(3):279-80. PubMed ID: 23276529 [No Abstract] [Full Text] [Related]
25. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand. Kuanprasert S; Dettrairat S; Palacajornsuk P; Kunachiwa W; Phrommintikul A J Med Assoc Thai; 2009 Dec; 92(12):1597-601. PubMed ID: 20043560 [TBL] [Abstract][Full Text] [Related]
26. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479 [TBL] [Abstract][Full Text] [Related]
27. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619 [TBL] [Abstract][Full Text] [Related]
28. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms. Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897 [TBL] [Abstract][Full Text] [Related]
29. Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors. D'Andrea G; D'Ambrosio R; Margaglione M Blood Rev; 2008 May; 22(3):127-40. PubMed ID: 18234403 [TBL] [Abstract][Full Text] [Related]
30. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846 [TBL] [Abstract][Full Text] [Related]
31. Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypes. Kovac MK; Rakicevic LB; Radojkovic DP J Thromb Thrombolysis; 2011 Oct; 32(3):368-71. PubMed ID: 21638223 [TBL] [Abstract][Full Text] [Related]
32. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Spreafico M; Lodigiani C; van Leeuwen Y; Pizzotti D; Rota LL; Rosendaal F; Mannucci PM; Peyvandi F Pharmacogenomics; 2008 Sep; 9(9):1237-50. PubMed ID: 18781852 [TBL] [Abstract][Full Text] [Related]
33. The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years. Nowak-Göttl U; Dietrich K; Kruempel A; Geisen C; Mitchell LG Blood Cells Mol Dis; 2017 Sep; 67():54-58. PubMed ID: 28284562 [TBL] [Abstract][Full Text] [Related]
34. [Pharmacogenetics and interindividual variability in drug response: cytochrome P-450 2C9 and coumarin anticoagulants]. Becquemont L; Verstuyft C; Jaillon P Bull Acad Natl Med; 2006 Jan; 190(1):37-49; discussion 50-3. PubMed ID: 16878445 [TBL] [Abstract][Full Text] [Related]